Postoperative long‑term outcomes of acute normovolemic hemodilution in pancreatic cancer : A propensity score matching analysis
Copyright: © 2024 Wakiya et al..
Acute normovolemic hemodilution (ANH) is a useful intraoperative blood conservation technique. However, the impact on long-term outcomes in pancreatic ductal adenocarcinoma (PDAC) remains unclear. The present study investigated the impact of ANH on long-term outcomes in patients with PDAC undergoing radical surgery. Data from 155 resectable PDAC cases were collected. Patients were categorized according to whether or not they had received intraoperative allogeneic blood transfusion (ABT) or ANH. Postoperative complications, recurrence-free survival (RFS) and disease-specific survival (DSS), before and after propensity score matching (PSM), were compared among patients who did and did not receive ANH. A total of 44 patients (28.4%) were included in the ANH group and 30 patients (19.4%) were included in the ABT group; 81 (52.3%) patients, comprising the standard management (STD) group, received neither ANH nor ABT. The ABT group had the worst prognosis among them. Before PSM, ANH was significantly associated with decreased RFS (P=0.043) and DSS (P=0.029) compared with the STD group before applying Bonferroni correction; however, no significant difference was observed after applying Bonferroni correction. Cox regression analysis identified ANH as an independent prognostic factor for RFS [relative risk (RR), 1.696; P=0.019] and DSS (RR, 1.876; P=0.009). After PSM, the ANH group exhibited less favorable RFS [median survival time (MST), 12.1 vs. 18.1 months; P=0.097] and DSS (MST, 32.1 vs. 50.5 months; P=0.097) compared with the STD group; however, these differences were not statistically significant. In conclusion, while ANH was not as harmful as ABT, it exhibited potentially more negative effects on long-term postoperative outcomes in PDAC than STD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Oncology letters - 27(2024), 5 vom: 01. Apr., Seite 236 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wakiya, Taiichi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ANH |
|---|
| Anmerkungen: |
Date Revised 12.04.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3892/ol.2024.14369 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370905091 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370905091 | ||
| 003 | DE-627 | ||
| 005 | 20240412233537.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240411s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3892/ol.2024.14369 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1373.xml |
| 035 | |a (DE-627)NLM370905091 | ||
| 035 | |a (NLM)38601182 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wakiya, Taiichi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Postoperative long‑term outcomes of acute normovolemic hemodilution in pancreatic cancer |b A propensity score matching analysis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 12.04.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright: © 2024 Wakiya et al. | ||
| 520 | |a Acute normovolemic hemodilution (ANH) is a useful intraoperative blood conservation technique. However, the impact on long-term outcomes in pancreatic ductal adenocarcinoma (PDAC) remains unclear. The present study investigated the impact of ANH on long-term outcomes in patients with PDAC undergoing radical surgery. Data from 155 resectable PDAC cases were collected. Patients were categorized according to whether or not they had received intraoperative allogeneic blood transfusion (ABT) or ANH. Postoperative complications, recurrence-free survival (RFS) and disease-specific survival (DSS), before and after propensity score matching (PSM), were compared among patients who did and did not receive ANH. A total of 44 patients (28.4%) were included in the ANH group and 30 patients (19.4%) were included in the ABT group; 81 (52.3%) patients, comprising the standard management (STD) group, received neither ANH nor ABT. The ABT group had the worst prognosis among them. Before PSM, ANH was significantly associated with decreased RFS (P=0.043) and DSS (P=0.029) compared with the STD group before applying Bonferroni correction; however, no significant difference was observed after applying Bonferroni correction. Cox regression analysis identified ANH as an independent prognostic factor for RFS [relative risk (RR), 1.696; P=0.019] and DSS (RR, 1.876; P=0.009). After PSM, the ANH group exhibited less favorable RFS [median survival time (MST), 12.1 vs. 18.1 months; P=0.097] and DSS (MST, 32.1 vs. 50.5 months; P=0.097) compared with the STD group; however, these differences were not statistically significant. In conclusion, while ANH was not as harmful as ABT, it exhibited potentially more negative effects on long-term postoperative outcomes in PDAC than STD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ANH | |
| 650 | 4 | |a blood transfusion | |
| 650 | 4 | |a pancreatic neoplasms | |
| 650 | 4 | |a prognosis | |
| 650 | 4 | |a propensity score | |
| 700 | 1 | |a Ishido, Keinosuke |e verfasserin |4 aut | |
| 700 | 1 | |a Kimura, Norihisa |e verfasserin |4 aut | |
| 700 | 1 | |a Nagase, Hayato |e verfasserin |4 aut | |
| 700 | 1 | |a Kanda, Taishu |e verfasserin |4 aut | |
| 700 | 1 | |a Kubota, Shunsuke |e verfasserin |4 aut | |
| 700 | 1 | |a Fujita, Hiroaki |e verfasserin |4 aut | |
| 700 | 1 | |a Takahashi, Yoshiya |e verfasserin |4 aut | |
| 700 | 1 | |a Yamamoto, Takeshi |e verfasserin |4 aut | |
| 700 | 1 | |a Chida, Kohei |e verfasserin |4 aut | |
| 700 | 1 | |a Saito, Junichi |e verfasserin |4 aut | |
| 700 | 1 | |a Hirota, Kazuyoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Hakamada, Kenichi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oncology letters |d 2010 |g 27(2024), 5 vom: 01. Apr., Seite 236 |w (DE-627)NLM201171317 |x 1792-1082 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2024 |g number:5 |g day:01 |g month:04 |g pages:236 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3892/ol.2024.14369 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2024 |e 5 |b 01 |c 04 |h 236 | ||